L. Torre, F. Bray, R. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, 2012, CA: A Cancer Journal for Clinicians, vol.6, issue.19, pp.87-108, 2012.
DOI : 10.1038/nrc1948

M. Saito, K. Shiraishi, H. Kunitoh, S. Takenoshita, J. Yokota et al., Gene aberrations for precision medicine against lung adenocarcinoma, Cancer Science, vol.48, issue.6, pp.713-733, 2016.
DOI : 10.1038/ng.3470
URL : http://onlinelibrary.wiley.com/doi/10.1111/cas.12941/pdf

M. Soda, Y. Choi, M. Enomoto, S. Takada, Y. Yamashita et al., Identification of the transforming EML4???ALK fusion gene in non-small-cell lung cancer, Nature, vol.276, issue.7153, pp.561-567, 2007.
DOI : 10.1016/S0002-9440(10)62574-6

A. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crinó et al., -Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-94, 1056.
DOI : 10.1056/NEJMoa1214886

K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu et al., Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer, Cell, vol.131, issue.6, pp.1190-203, 2007.
DOI : 10.1016/j.cell.2007.11.025

T. Kohno, H. Ichikawa, Y. Totoki, K. Yasuda, M. Hiramoto et al., KIF5B-RET fusions in lung adenocarcinoma, Nature Medicine, vol.62, issue.3, pp.375-382, 2012.
DOI : 10.2165/11595310-000000000-00000

A. Uguen, D. Braekeleer, and M. , fusions in cancer: a review, Future Oncology, vol.12, issue.16, pp.1911-1939, 2016.
DOI : 10.1371/journal.pone.0083380

L. Mulligan, RET revisited: expanding the oncogenic portfolio, Nature Reviews Cancer, vol.7, issue.3, pp.173-86, 2014.
DOI : 10.1038/nrendo.2011.141

C. Birchmeier, S. Sharma, and M. Wigler, Expression and rearrangement of the ROS1 gene in human glioblastoma cells., Proceedings of the National Academy of Sciences, vol.84, issue.24, pp.9270-9274, 1987.
DOI : 10.1073/pnas.84.24.9270

T. Kohno, T. Nakaoku, K. Tsuta, K. Tsuchihara, S. Matsumoto et al., Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer, Transl Lung Cancer Res, vol.4, pp.156-64, 2015.

F. Hirsch, K. Suda, J. Wiens, P. Bunn, and . Jr, New and emerging targeted treatments in advanced non-small-cell lung cancer, The Lancet, vol.388, issue.10048, pp.1012-1036, 2016.
DOI : 10.1016/S0140-6736(16)31473-8

C. Steuer, M. Behera, L. Berry, S. Kim, M. Rossi et al., Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium, Cancer, vol.341, issue.5, pp.766-72, 2016.
DOI : 10.1056/NEJM199910143411606

N. Yamaguchi, P. Vanderlaan, E. Folch, D. Boucher, H. Canepa et al., Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice, Lung Cancer, vol.82, issue.1, pp.31-38, 2013.
DOI : 10.1016/j.lungcan.2013.07.013

Q. Zhu, P. Zhan, X. Zhang, T. Lv, and Y. Song, Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis, Transl Lung Cancer Res, vol.4, pp.300-309, 2015.

C. Lin, S. Wang, W. Xie, J. Chang, and Y. Gan, The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis, Cancer Biology & Therapy, vol.28, issue.4, pp.1019-1047, 2015.
DOI : 10.1097/JTO.0000000000000234

S. Lee, B. Lee, M. Hong, J. Song, K. Jung et al., Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma, Modern Pathology, vol.1795, issue.4, pp.468-79, 2015.
DOI : 10.1097/JTO.0b013e318274a83e

A. Warth, T. Muley, H. Dienemann, B. Goeppert, A. Stenzinger et al., expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases, Histopathology, vol.24, issue.2, pp.187-94, 2014.
DOI : 10.1093/annonc/mdt071

P. Jurmeister, D. Lenze, E. Berg, S. Mende, F. Schäper et al., Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing, Lung Cancer, vol.87, issue.2, pp.122-131, 2015.
DOI : 10.1016/j.lungcan.2014.11.018

S. Michels, A. Scheel, M. Scheffler, A. Schultheis, O. Gautschi et al., Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients, Journal of Thoracic Oncology, vol.11, issue.1, pp.122-129, 2016.
DOI : 10.1016/j.jtho.2015.09.016

M. Sarfaty, A. Moore, V. Neiman, E. Dudnik, M. Ilouze et al., RET fusion lung carcinoma: response to therapy and clinical features in a case series of 14 patients. Clin Lung Cancer

M. Kobayashi, M. Sonobe, T. Takahashi, A. Yoshizawa, R. Kikuchi et al., Detection of ALK fusion in lung cancer using fluorescence in situ hybridization. www.impactjournals.com/oncotarget Asian Cardiovasc Thorac Ann, pp.426-457, 2012.

R. Wang, Y. Pan, C. Li, H. Zhang, D. Garfield et al., Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas, Journal of Thoracic Oncology, vol.9, issue.6, pp.760-768, 2014.
DOI : 10.1097/JTO.0b013e3182a406d1

Z. Song, X. Yu, and Y. Zhang, Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients, Cancer Biology & Therapy, vol.18, issue.11
DOI : 10.1080/15384047.2015.1046649

A. Platt, J. Morten, J. Q. Elvin, P. Womack, C. Su et al., A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies, BMC Cancer, vol.31, issue.1, pp.171-181, 2015.
DOI : 10.1097/JTO.0b013e31828a4d07

S. Clavé, J. Gimeno, A. Muñoz-mármol, J. Vidal, N. Reguart et al., ROS1 copy number alterations are frequent in non-small cell lung cancer, Oncotarget, vol.7, issue.7, pp.8019-8047, 2016.
DOI : 10.18632/oncotarget.6921

H. Lee, H. Seol, J. Kim, S. Chun, Y. Suh et al., ROS1 Receptor Tyrosine Kinase, a Druggable Target, is Frequently Overexpressed in Non-Small Cell Lung Carcinomas Via Genetic and Epigenetic Mechanisms, Annals of Surgical Oncology, vol.455, issue.1, pp.200-208, 2013.
DOI : 10.1038/nature07385

U. Peretti, R. Ferrara, S. Pilotto, S. Kinspergher, M. Caccese et al., ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations, Respiratory Research, vol.4, issue.1, pp.105-115, 2016.
DOI : 10.1126/scitranslmed.3003316

Y. Jin, P. Sun, H. Kim, E. Park, H. Shim et al., ROS1 gene rearrangement and copy number gain in non-small cell lung cancer, Virchows Archiv, vol.20, issue.1, pp.45-52, 2015.
DOI : 10.1245/s10434-012-2553-6

H. Yang and B. Horten, Gain of copy number and amplification of the RET gene in lung cancer, Experimental and Molecular Pathology, vol.97, issue.3, pp.465-474, 2014.
DOI : 10.1016/j.yexmp.2014.10.002

Y. Seki, T. Mizukami, and T. Kohno, Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks, Biomolecules, vol.48, issue.4, pp.2464-76, 2015.
DOI : 10.1038/nature09744

T. Mizukami, K. Shiraishi, Y. Shimada, H. Ogiwara, K. Tsuta et al., Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.9, issue.5, pp.622-652, 2014.
DOI : 10.1097/JTO.0000000000000135

A. Shaw, P. Hsu, M. Awad, and J. Engelman, Tyrosine kinase gene rearrangements in epithelial malignancies, Nature Reviews Cancer, vol.71, issue.11, pp.772-87, 2013.
DOI : 10.1158/1538-7445.AM2011-3571

W. Li, J. Zhang, L. Guo, S. Chuai, L. Shan et al., Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events??in ALK Fusion Patterns in NSCLC that Responds??to Crizotinib Treatment, Journal of Thoracic Oncology, vol.12, issue.1, pp.94-101, 2017.
DOI : 10.1016/j.jtho.2016.08.145

R. Penzel, P. Schirmacher, and A. Warth, A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK, Journal of Thoracic Oncology, vol.7, issue.7, pp.1198-1207, 2012.
DOI : 10.1097/JTO.0b013e3182598af3

S. Kim, T. Ahn, H. Bang, J. Ham, J. Kim et al., Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion, Oncotarget, vol.8, issue.9, pp.15014-15036, 2017.
DOI : 10.18632/oncotarget.14788

J. Jang, X. Wang, P. Vedell, J. Wen, J. Zhang et al., Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH??and IHC in Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.11, issue.11, pp.1891-900, 2016.
DOI : 10.1016/j.jtho.2016.06.001

A. Mansfield, S. Murphy, F. Harris, S. Robinson, R. Marks et al., rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib, Annals of Oncology, vol.59, issue.11, pp.2111-2118, 2016.
DOI : 10.1158/2159-8290.CD-13-0846

T. Kodama, N. Motoi, H. Ninomiya, H. Sakamoto, K. Kitada et al., A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line, Journal of Thoracic Oncology, vol.9, issue.11, pp.1638-1684, 2014.
DOI : 10.1097/JTO.0000000000000311

D. Costa, S. Kobayashi, S. Pandya, W. Yeo, Z. Shen et al., CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib, Journal of Clinical Oncology, vol.29, issue.15, pp.443-448, 2011.
DOI : 10.1200/JCO.2010.34.1313

R. Rosell and N. Karachaliou, RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer, The Lancet Oncology, vol.17, issue.12, pp.1623-1628, 2016.
DOI : 10.1016/S1470-2045(16)30557-5

A. Drilon, N. Rekhtman, M. Arcila, L. Wang, A. Ni et al., Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial, The Lancet Oncology, vol.17, issue.12, pp.1653-60, 2016.
DOI : 10.1016/S1470-2045(16)30562-9

S. Lee, J. Lee, M. Ahn, D. Kim, J. Sun et al., Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial, Ann Oncol, vol.28, pp.292-299, 2017.

K. Yoh, T. Seto, M. Satouchi, M. Nishio, N. Yamamoto et al., Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial, The Lancet Respiratory Medicine, vol.5, issue.1, pp.42-50, 2017.
DOI : 10.1016/S2213-2600(16)30322-8

J. Lin, E. Kennedy, L. Sequist, P. Brastianos, K. Goodwin et al., Clinical Activity of Alectinib in Advanced RET -Rearranged Non???Small Cell Lung Cancer, Journal of Thoracic Oncology, vol.11, issue.11, pp.2027-2059, 2016.
DOI : 10.1016/j.jtho.2016.08.126

V. Velcheti, T. Hida, K. Reckamp, J. Yang, H. Nokihara et al., Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung, Annals of Oncology, vol.27, issue.suppl_6, pp.416-54, 2016.
DOI : 10.1093/annonc/mdw383.05

A. Drilon, I. Bergagnini, L. Delasos, J. Sabari, K. Woo et al., -rearranged lung cancers, Annals of Oncology, vol.27, issue.7, pp.1286-91, 2016.
DOI : 10.1093/annonc/mds242

J. Gainor, A. Shaw, L. Sequist, X. Fu, C. Azzoli et al., EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis, Clinical Cancer Research, vol.22, issue.18, pp.4585-93, 2016.
DOI : 10.1158/1078-0432.CCR-15-3101

M. Saito, Y. Shimada, K. Shiraishi, H. Sakamoto, K. Tsuta et al., Development of Lung Adenocarcinomas with Exclusive Dependence on Oncogene Fusions, Cancer Research, vol.75, issue.11, pp.2264-71, 2015.
DOI : 10.1158/0008-5472.CAN-14-3282